Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 1, 2026 · Other material event · Financial statements
Outlook Therapeutics, Inc.
8
Other material event
Jun 1, 2026
| ItemItem | Disclosure |
|---|---|
| Item 8.01 | Other events the company considers material |
| Item 9.01 | Financial statements and exhibits |
Outlook Therapeutics, Inc. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. 1 Outlook Therapeutics Announces Resubmission of Biologics License Application to U. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) ISELIN, N.
This filing reports Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Outlook Therapeutics, Inc. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
